Spero Therapeutics (SPRO) Debt/Equity Ratio: History & Chart

Spero Therapeutics, Inc.(SPRO)

Biotechnology · Cambridge, MA

$1.19+0.03 (+2.59%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Spero Therapeutics, Inc.

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

25 employees

sperotherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Esther Rajavelu

View full financials

SPRO Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.05

DEBT TO EQUITY RATIO AVG TTM

0.08

DEBT TO EQUITY RATIO AVG 3Y

0.08

DEBT TO EQUITY RATIO AVG 5Y

0.08

DEBT TO EQUITY RATIO AVG 10Y

0.05

DEBT TO EQUITY RATIO AVG 15Y

N/A

DEBT TO EQUITY RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-38.96%

CURRENT VS 3Y AVG

-42.63%

CURRENT VS 5Y AVG

-43.15%

CURRENT VS 10Y AVG

-14.58%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.11

median of 774 covered companies

CURRENT VS SECTOR MEDIAN

-57.98%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Spero Therapeutics, Inc. (SPRO)	$68.90M	0.05	0.08	0.08	0.08
Champions Oncology, Inc. (CSBR)vs ›	$69.61M	2.82	1.39	1.54	1.39
Fortress Biotech, Inc. (FBIO)vs ›	$68.10M	0.39	2.42	2.91	2.20
iBio, Inc. (IBIO)vs ›	$67.52M	0.03	0.14	0.40	0.38
Tiziana Life Sciences Ltd (TLSA)vs ›	$70.63M	8.77	4.40	2.21	1.48
Gain Therapeutics, Inc. (GANX)vs ›	$71.23M	0.05	0.07	0.07	0.09
Gossamer Bio, Inc. (GOSS)vs ›	$65.87M	N/A	5.13	7.62	5.19
Cingulate Inc. (CING)vs ›	$65.86M	0.27	2.09	1.90	1.47
XBiotech Inc. (XBIT)vs ›	$65.85M	0.00	0.03	0.01	0.01
Verrica Pharmaceuticals Inc. (VRCA)vs ›	$72.32M	0.42	0.07	0.80	0.97

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Spero Therapeutics, Inc. (SPRO)

$68.90M

0.05

0.08

Champions Oncology, Inc. (CSBR)vs ›

$69.61M

2.82

1.39

1.54

1.39

Fortress Biotech, Inc. (FBIO)vs ›

$68.10M

0.39

2.42

2.91

2.20

iBio, Inc. (IBIO)vs ›

$67.52M

0.03

0.14

0.40

0.38

Tiziana Life Sciences Ltd (TLSA)vs ›

$70.63M

8.77

4.40

2.21

1.48

Gain Therapeutics, Inc. (GANX)vs ›

$71.23M

0.05

0.07

0.09

Gossamer Bio, Inc. (GOSS)vs ›

$65.87M

N/A

5.13

7.62

5.19

Cingulate Inc. (CING)vs ›

$65.86M

0.27

2.09

1.90

1.47

XBiotech Inc. (XBIT)vs ›

$65.85M

0.00

0.03

0.01

Verrica Pharmaceuticals Inc. (VRCA)vs ›

$72.32M

0.42

0.07

0.80

0.97

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Spero Therapeutics, Inc. (SPRO)?

The debt to equity ratio for SPRO stock is 0.05.

Is Spero Therapeutics, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 0.05 is 43% below its 5-year average of 0.08, near the low end of its 5-year range (0.05–0.93).

What is the TTM average debt to equity ratio for Spero Therapeutics, Inc. (SPRO)?

The TTM average debt to equity ratio for SPRO stock is 0.08.

What is the 3Y average debt to equity ratio for Spero Therapeutics, Inc. (SPRO)?

The 3Y average debt to equity ratio for SPRO stock is 0.08.

What is the 5Y average debt to equity ratio for Spero Therapeutics, Inc. (SPRO)?

The 5Y average debt to equity ratio for SPRO stock is 0.08.

What is the 10Y average debt to equity ratio for Spero Therapeutics, Inc. (SPRO)?

The 10Y average debt to equity ratio for SPRO stock is 0.05.

DATE	DEBT TO EQUITY RATIO
2026-06-30	0.05
2026-03-31	0.05
2025-12-31	0.05
2025-09-30	0.13
2025-06-30	0.11
2025-03-31	0.12
2024-12-31	0.09
2024-09-30	0.07
2024-06-30	0.06
2024-03-31	0.05
2023-12-31	0.05
2023-09-30	0.11
2023-06-30	0.11
2023-03-31	0.10
2022-12-31	0.09
2022-09-30	0.21
2022-06-30	0.19
2022-03-31	0.93
2021-12-31	0.08
2021-09-30	0.06
2021-06-30	0.08
2021-03-31	0.06
2020-12-31	0.06
2020-09-30	0.06
2020-06-30	0.08
2020-03-31	0.07
2019-12-31	0.07
2019-09-30	0.05
2019-06-30	0.04
2019-03-31	0.04
2018-12-31	0.00
2018-09-30	0.00
2018-06-30	0.00
2018-03-31	0.00
2017-12-31	0.00
2017-09-30	0.00
2017-06-30	0.00
2017-03-31	0.00
2016-12-31	0.00
2016-09-30	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

0.05

2026-03-31

0.05

2025-12-31

0.05

2025-09-30

0.13

2025-06-30

0.11

2025-03-31

0.12

2024-12-31

0.09

2024-09-30

0.07

2024-06-30

0.06

2024-03-31

0.05

2023-12-31

0.05

2023-09-30

0.11

2023-06-30

0.11

2023-03-31

0.10

2022-12-31

0.09

2022-09-30

0.21

2022-06-30

0.19

2022-03-31

0.93

2021-12-31

0.08

2021-09-30

0.06

2021-06-30

0.08

2021-03-31

0.06

2020-12-31

0.06

2020-09-30

0.06

2020-06-30

0.08

2020-03-31

0.07

2019-12-31

0.07

2019-09-30

0.05

2019-06-30

0.04

2019-03-31

0.04

2018-12-31

0.00

2018-09-30

0.00

2018-06-30

0.00

2018-03-31

0.00

2017-12-31

0.00

2017-09-30

0.00

2017-06-30

0.00

2017-03-31

0.00

2016-12-31

0.00

2016-09-30

0.00

Debt to Equity Ratio: 0.05

SPRO Debt to Equity Ratio

SPRO Average Debt to Equity Ratio Chart

SPRO Current vs Average Debt to Equity Ratio Chart

SPRO Debt to Equity Ratio Metrics

SPRO Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

SPRO Debt to Equity Ratio History

Related Metrics